CTOs on the Move

Copernicus

www.cgsys.com

 
Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgsys.com
  • 11000 Cedar Ave Ste 145
    Cleveland, OH USA 44106
  • Phone: 216.231.0227

Executives

Name Title Contact Details

Similar Companies

BD Biosciences

BD Biosciences is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erasca

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology`s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn`t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Bayer AG

Bayer AG is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

New Century Hospice

New Century Hospice is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cue Biopharma

Cue Biopharma™ is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. We design biologics to engage and modulate the activity of disease-associated T cells in the patient`s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. We believe our biologics allow us to target antigen-specific T cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the Cue Biologics Platform™. This flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. Headquartered in Kendall Square, Cambridge, MA, we are led by an experienced management team and scientific and clinical advisory board (SAB/CAB) with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.